Endocrine Aspects of Healthy Brain Aging

Clinics in Geriatric Medicine

Volumn 26, Issue 1, 2010, Pages 57-74

  Bassil, Nazem ^a   Morley, John E ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; Hormones; Metabolic alteration

Indexed keywords

AMYLOID BETA PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GONADOTROPIN; GROWTH HORMONE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; MELATONIN; PLACEBO; PRASTERONE; PREGNENOLONE; SOMATOMEDIN C; TESTOSTERONE; VITAMIN D;

AGING; ALZHEIMER DISEASE; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFICACY; ENDOCRINE FUNCTION; ENZYME SYNTHESIS; GENETIC RISK; GLYCEMIC CONTROL; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; MENTAL HEALTH; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

AGING; BRAIN; COGNITION DISORDERS; DEMENTIA; ENDOCRINE SYSTEM DISEASES; HUMANS;

EID: 76749109948     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2009.12.004     Document Type: Review

References (186)

1. Morley J.E. A brief history of geriatrics. J Gerontol A Biol Sci Med Sci 59 (2004) 1132-1152
2. Morley J.E., and Perry III H.M. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med 135 (2000) 370-378
3. Morley J.E., Flood J., and Silver A.J. Effects of peripheral hormones on memory and ingestive behaviors. Psychoneuroendocrinology 17 (1992) 391-399
4. Lee M., and Chodosh J. Dementia and life expectancy: what do we know?. J Am Med Dir Assoc 10 (2009) 466-471
5. Samus Q.M., Mayer L., Onyike C.U., et al. Correlates of functional dependence among recently admitted assisted living residents with and without dementia. J Am Med Dir Assoc 10 (2009) 323-329
6. Morley J.E. Managing persons with dementia in the nursing home: high touch trumps high tech. J Am Med Dir Assoc 9 (2008) 139-146
7. Kaufer D.I., Williams C.S., Braaten A.J., et al. Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of 3 tests. J Am Med Dir Assoc 9 (2008) 586-593
8. Volicer L. Behaviors in advanced dementia. J Am Med Dir Assoc 10 (2009) 146
9. Irie F., Fitzpatrick A.L., Lopez O.L., et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE {varepsilon}4: The Cardiovascular Health Study Cognition Study. Arch Neurol 65 1 (2008) 89-93
10. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51 4 (2002) 1256-1262
11. MacKnight C., Rockwood K., Awalt E., et al. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14 2 (2002) 77-83
12. Hassing L.B., Johansson B., Nilsson S.E., et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 14 3 (2002) 239-248
13. Schnaider Beeri M., Goldbourt U., Silverman J.M., et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63 (2004) 1902-1907
14. Flood J.F., Mooradian A.D., and Morley J.E. Characteristics of learning and memory in steptozocin-induced diabetic mice. Diabetes 39 (1999) 1391-1398
15. Mooradian A.D., Perryman K., Fitten J., et al. Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies. Arch Intern med 148 (1988) 2369-2372
16. Messinger-Rapport B.J., Thomas D.R., Gammack J.K., et al. Clinical update on nursing home medicine: 2008. J Am Med Dir Assoc 9 (2008) 460-475
17. Biessels G.J., Staekenborg S., Brunner E., et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5 1 (2006) 64-74 [Erratum in: Lancet Neurol 2006;5(2):113]
18. Abbatecola A.M., Rizzo M.R., Barbieri M., et al. Postprandial plasmaglucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67 2 (2006) 235-240
19. Munshi M., Grande L., Hayes M., et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 29 8 (2006) 1794-1799
20. Xu W.L., Qiu C.X., Wahlin A., et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63 7 (2004) 1181-1186
21. Biessels G.J., De Leeuw F.E., Lindeboom J., et al. Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatr 77 3 (2006) 304-307
22. Tong M., and de la Monte S.M. Ceramide-mediated neurodegeneration: relevance to diabetes-associated neurodegeneration. J Alzheimers Dis 16 (2009) 705-714
23. Steen E., Terry B.M., Rivera E.J., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J Alzheimers Dis 7 (2005) 63-80
24. Arboleda G., Huang T.J., Waters C., et al. Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells. Eur J Neurosci 25 (2007) 3030-3038
25. Peila R., Rodriguez B.L., White L.R., et al. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63 2 (2004) 228-233
26. Burns J.M., Donnelly J.E., Anderson H.S., et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 69 11 (2007) 1094-1104
27. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia. The Rotterdam Study. Neurology 53 9 (1999) 1937-1942
28. Rosenthal M.J., Fajardo M., Gilmore S., et al. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 21 (1998) 231-235
29. Mazza A.D., and Morley J.E. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 8 (2007) 489-492
30. Flaherty J.H., Shay K., Weir C., et al. The development of a mental status vital sign for use across the spectrum of care. J Am Med Dir Assoc 10 (2009) 379-380
31. Flaherty J.H., Rudolph J., Shay K., et al. Delirium is a serious and under-recognized problem: why assessment of mental status should be the sixth vital sign. J Am Med Dir Assoc 8 (2007) 273-275
32. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. J Neurosci Res 72 2 (2003) 141-146
33. Michikawa M. The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. Mol Neurobiol 27 1 (2003) 1-12
34. Whitmer R.A., Sidney S., Selby J., et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 2 (2005) 277-281
35. Solomon A., Kåreholt I., Ngandu T., et al. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68 10 (2007) 751-756
36. Kalmijn S., van Boxtel M.P., Ocké M., et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 62 2 (2004) 275-280
37. Engelhart M.J., Geerlings M.I., Ruitenberg A., et al. Diet and risk of dementia. Does fat matter?: the Rotterdam Study. Neurology 59 12 (2002) 1915-1921
38. Moroney J.T., Tang M.X., Berglund L., et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 282 3 (1999) 254-259
39. Reitz C., Tang M.X., Luchsinger J., et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61 5 (2004) 705-714
40. Dufouil C., Richard F., Fievet N., et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64 9 (2005) 1531-1538
41. Tan Z.S., Seshadri S., Beiser A., et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 163 9 (2003) 1053-1057
42. Reitz C., Luchsinger J., Tang M.X., et al. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64 8 (2005) 1378-1383
43. Li G., Shofer J.B., Kukull W.A., et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65 7 (2005) 1045-1050
44. Mielke M.M., Zandi P.P., Sjögren M., et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64 10 (2005) 1689-1695
45. Stewart R., White L.R., Xue Q.L., et al. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 64 1 (2007) 103-107
46. Kirsch C., Eckert G.P., and Mueller W.E. Statin effects on cholesterol microdomains in brain plasma membranes. Biochem Pharmacol 65 5 (2003) 843-856
47. Crisby M., Carlson L.A., and Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 16 3 (2002) 131-136
48. Jick H., Zornberg G.L., Jick S.S., et al. Statins and the risk of dementia. Lancet 356 9242 (2000) 1627-1631 [Erratum in: Lancet 2001;357(9255):562]
49. Rodriguez E.G., Dodge H.H., Birzescu M.A., et al. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc 50 11 (2002) 1852-1856
50. Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98 10 (2001) 5856-5861
51. Cramer C., Haan M.N., Galea S., et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71 5 (2008) 344-350
52. Rea T.D., Breitner J.C., and Psaty B.M. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62 7 (2005) 1047-1051
53. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
54. Bernick C., Katz R., Smith N.L., et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 65 9 (2005) 1388-1394
55. Scott H.D., and Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 4 (2001) CD003160
56. Essink-Bot M.L., Pereria J., Packer C., et al. Cross-national comparability of burden of disease estimates: the European Disability Weights Project. Bull World Health Organ 80 8 (2002) 644-652
57. Lamberts S.W.J. The endocrinology of aging and the brain. Arch Neurol 59 (2002) 1709-1711
58. Angelini A., Bendini C., Neviani F., et al. Insulin-like growth factor-1 (IGF-1): relation with cognitive functioning and neuroimaging marker of brain damage in a sample of hypertensive elderly subjects. Arch Gerontol Geriatr 49 Suppl 1 (2009) 5-12
59. Harvey J. Leptin: a multifaceted hormone in the central nervous system. Mol Neurobiol 28 (2003) 245-258
60. Isidori A.M., Strollo F., Morè M., et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 85 5 (2000) 1954-1962
61. Funahashi H., Yada T., Suzuki R., et al. Distribution, function, and properties of leptin receptors in the brain. Int Rev Cytol 224 (2003) 1-27
62. O'Malley D., MacDonald N., Mizielinska S., et al. Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol Cell Neurosci 35 (2007) 559-572
63. Harvey J., Shanley L.J., O'Malley D., et al. Leptin: a potential cognitive enhancer?. Biochem Soc Trans 33 (2005) 1029-1032
64. Irving A.J., Wallace L., Durakoglugil D., et al. Leptin enhances NR2B-mediated N-methyl-D-aspartate responses via a mitogen-activated protein kinase-dependent process in cerebellar granule cells. Neuroscience 138 (2006) 1137-1148
65. Tezapsidis N., Johnston J.M., Smith M.A., et al. Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 16 4 (2009) 731-740
66. Li X.L., Aou S., Oomura Y., et al. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113 3 (2002) 607-615
67. Fewlass D.C., Noboa K., Pi-Sunyer F.X., et al. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18 15 (2004) 1870-1878
68. Power D.A., Noel J., Collins R., et al. Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement Geriatr Cogn Disord 12 2 (2001) 167-170
69. Holden K.F., Lindquist K., Tylavsky F.A., et al. Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol Aging 30 9 (2009) 1483-1489
70. Joshi S., and Morley J.E. Cognitive impairment. Med Clin North Am 90 (2006) 769-787
71. Farr S.A., Yamada K.A., Butterfield D.A., et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 149 (2008) 2628-2636
72. Vanhanen M., Koivisto K., Moilanen L., et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67 5 (2006) 843-847
73. Razay G., Vreugdenhil A., and Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 64 1 (2007) 93-96
74. Kalmijn S., Foley D., White L., et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20 10 (2000) 2255-2260
75. Yaffe K., Kanaya A., Lindquist K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 18 (2004) 2237-2242
76. Morley J.E., Kaiser F.E., Perry III H.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46 (1997) 410-413
77. Morley J.E., Patrick P., and Perry III H.M. Evaluation of assays available to measure free testosterone. Metabolism 51 (2002) 554-559
78. Wang C., Nieschlag E., Swerdloff R.S., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 12 (2009) 5-12
79. Wittert G.A., Chapman I.M., Haren M.T., et al. Oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 50 (2005) 124-133
80. Abelland van Kan G., Rolland Y.M., Morley J.E., et al. Frailty: toward a clinical definition. J Am Med Dir Assoc 9 (2008) 71-72
81. Flood J.F., Farr S.A., Kaiser F.E., et al. Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory. Physiol Behav 57 (1995) 669-673
82. Gillett M.J., Martins R.N., Clarnette R.M., et al. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis 5 (2003) 267-269
83. Morley J.E., Kaiser F., Raum W.J., et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A 94 (1997) 7537-7542
84. Moffat S.D., Zonderman A.B., Metter E.J., et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 62 (2004) 188-193
85. Hogervorst E., Bandelow S., Combrinck M., et al. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 39 (2004) 1633-1639
86. Moffat S.D. Effects of testosterone on cognitive and brain aging in elderly men. Ann N Y Acad Sci 1055 (2005) 80-92
87. Chu L.W., Tam S., Lee P.W., et al. Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 68 4 (2008) 589-598
88. McKeever W.F., and Deyo A. Testosterone, dihydrotestosterone and spatial task performance of males. Bull Psychon Soc 28 (1990) 305-308
89. Drummond E.S., Harvey A.R., Martins R.N., et al. Androgens and Alzheimer's disease. Curr Opin Endocrinol Diabetes Obes 16 (2009) 254-259
90. Galea L.A., Uban K.A., Epp J.R., et al. Endocrine regulation of cognition and neuroplasticity: our pursuit to unveil the complex interaction between hormones, the brain, and behavior. Can J Exp Psychol 62 (2008) 247-260
91. Yaffe K., Lui L.-Y., Zmuda J., et al. Sex hormones and cognitive function in older men. J Am Geriatr Soc 50 (2002) 707-712
92. Thilers P.P., MacDonald S.W.S., and Herlitz A. The association between endogenous free testosterone and cognitive performance: a population based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 31 (2006) 565-576
93. Yeap B.B., Almeida O.P., Hyde Z., et al. Higher serum free testosterone is associated with better cognitive function in older men, whilst total testosterone is not. The Health In Men Study. Clin Endocrinol 68 (2008) 404-412
94. Yonker J.E., Eriksson E., Nilsson L.-G., et al. Negative association of testosterone on spatial visualisation in 35 to 80 year old men. Cortex 42 (2006) 376-386
95. Martin D.M., Wittert G., Burns N.R., et al. Testosterone and cognitive function in ageing men: data from the Florey Adelaide Male Ageing Study (FAMAS). Maturitas 57 (2007) 182-194
96. Burkhardt M.S., Foster J.K., Clarnet te R.M., et al. Interaction between testosterone and apolipoprotein E e4 status on cognition in healthy older men. J Clin Endocrinol Metab 91 (2006) 1168-1172
97. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 (2003) 1808-1811
98. Salminen E.K., Portin R.I., Koskinen A., et al. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 10 (2004) 7575-7582
99. Almeida O.P., Waterreus A., Spry N., et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29 8 (2004) 1071-1081
100. Hogervorst E., Williams J., Budge M., et al. Serum total testosterone is lower in men with Alzheimer's disease. Neuro Endocrinol Lett 22 3 (2001) 163-168
101. Bowen R.L., Isley J.P., and Atkinson R.L. An association of elevated serum gonadotropin concentrations and Alzheimer disease?. J Neuroendocrinol 12 4 (2000) 351-354
102. Gibbs R.B., and Gabor R. Estrogen and cognition: applying preclinical findings to clinical perspectives. J Neurosci Res 74 5 (2003) 637-643
103. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol 155 (2006) 773-781
104. Lyngdorf P., and Hemmingsen L. Epidemiology of erectile dysfunction and its risk factors: a practice-based study in Denmark. Int J Impot Res 16 (2004) 105-111
105. Orwoll ES, Oviatt SK, Biddle J, et al. Transdermal testosterone supplementation in normal older men. Proceedings of the 74th Meeting of The Endocrine Society, San Antonio, TX; 1992. p. 319.
106. Alexander G.M., Swerdloff R.S., Wang C., et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. Horm Behav 33 (1998) 85-94
107. Janowsky J.S., Chavez B., and Orwoll E. Sex steroids modify working memory. J Cogn Neurosci 12 (2000) 407-414
108. Cherrier M.M., Craft S., and Matsumoto A.H. Cognitive changes associated with supplementation of testosterone or dihydrotestosterone in mildly hypogonadal men: a preliminary report. J Androl 24 (2003) 568-576
109. Cherrier M.M., Matsumoto A.M., Amory J.K., et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64 (2005) 2063-2068
110. Lu P.H., Masterman D.A., Mulnard R., et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 63 (2006) 177-185
111. Maki P.M., Ernst M., London E.D., et al. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab 92 (2007) 4107-4114
112. Tan R.S., and Culberson J.W. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 45 (2003) 15-27
113. Kenny A.M., Fabregas G., Song C., et al. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 59 (2004) 75-78
114. Sih R., Morley J.E., Kaiser F.E., et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82 (1997) 1661-1667
115. Zarrouf F.A., Artz S., Griffith J., et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 15 (2009) 289-305
116. Vasudevan N., and Pfaff D.W. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocr Rev 28 (2007) 1-19
117. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 19 (2005) 1951-1959
118. Moult P.R., and Harvey J. Hormonal regulation of hippocampal dendritic morphology and synaptic plasticity. Cell Adh Migr 2 (2008) 269-275
119. Rocca W.A., Bower J.H., Maraganore D.M., et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69 11 (2007) 1074-1083
120. LeBlanc E.S., Janowsky J., Chan B.K., et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285 (2001) 1489-1499
121. Hogervorst E., Williams J., Budge M., et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. Neuroscience 101 (2000) 485-512
122. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
123. Espeland M.A., Rapp S.R., Shumaker S.A., et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 24 (2004) 2959-2968
124. Shumaker S.A., Legault C., Kuller L., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 (2004) 2947-2958
125. Henderson V.W., Benke K.S., Green R.C., et al. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatr 76 (2005) 103-105
126. Siegfried T. Neuroscience: it's all in the timing. Nature 445 (2007) 359-361
127. Gibbs R.G. Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol Aging 21 (2000) 107-116
128. Zandi P.P., Carlson M.C., Plassman B.L., et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288 (2002) 2123-2129
129. Farr S.A., Banks W.A., Uezu K., et al. DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice. Life Sci 75 (2004) 2775-2785
130. Haren M.T., Malmstrom T.K., Banks W.A., et al. Lower serum DHEAS levels are associated with a higher degree of physical disability and depressive symptoms in middle-aged to older African American women. Maturitas 57 (2007) 347-360
131. Morley J.E. Hormones and the aging process. J Am geriatr Soc 51 Suppl 7 (2003) S333-S337
132. Grimley Evans J., Malouf R., and Huppert F. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 4 (2006) CD006221
133. Flood J.F., Farr S.A., Johnson D.A., et al. Peripheral steroid sulfatase inhibition potentiates improvement of memory retention for hippocampally administered dehydroepiandrosterone sulfate but not pregnenolone sulfate. Psychoneuroendocrinology 24 (1999) 799-811
134. Flood J.F., Morley J.E., and Roberts E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdale is by far the most sensitive. Proc Natl Acad Sci U S A 92 (1995) 10806-10810
135. Flood J.F., Morley J.E., and Roberts E. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci U S A 89 (1992) 1567-1571
136. Lupien S.J., Wilkinson C.W., Briere S., et al. The modulatory effects of corticosteroids on cognition: studies in young human populations. Psychoneuroendocrinology 27 (2002) 401-416
137. Roozendaal. 1999 Curt P. Richter award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 25 3 (2000) 213-238
138. McEwen B.S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87 (2007) 873-904
139. In: Stuss D.T., and Knight R.T. (Eds). Principles of frontal lobe function (2002), Oxford University Press, New York 90-107
140. Yuen E.Y., Liu W., Karatsoreos I.N., et al. Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci U S A 106 (2009) 14075-14079
141. Mizoguchi K., Ishige A., Takeda S., et al. Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J Neurosci 24 (2004) 5492-5499
142. Joels M., Pu Z., Wiegert O., et al. Learning under stress: How does it work?. Trends Cogn Sci 10 (2006) 152-158
143. Joels M. Corticosteroid effects in the brain: U-shape it. Trends Pharmacol Sci 27 (2006) 244-250
144. Swanwick G.R., Kirby M., Bruce I., et al. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 155 2 (1998) 286-289
145. Näsman B., Olsson T., Seckl J.R., et al. Abnormalities in adrenal androgens, but not of glucocorticoids, in early Alzheimer's disease. Psychoneuroendocrinology 20 1 (1995) 83-94
146. Green K.N., Billings L.M., Roozendaal B., et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci 26 (2006) 9047-9056
147. Tsolaki M., Kounti F., Karamavrou S., et al. Severe psychological stress in elderly individuals: a proposed model of neurodegeneration and its implications. Am J Alzheimers Dis Other Demen 24 2 (2009) 85-94
148. Lee B.K., Glass T.A., McAtee M.J., et al. Association of salivary cortisol with cognitive function in the Baltimore memory study. Arch Gen Psychiatry 64 (2007) 810-818
149. Aisen P.S. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand, Suppl 176 (2000) 85-89
150. Peskind E.R., Wilkinson C.W., Petrie E.C., et al. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 56 8 (2001) 1094-1098
151. de Quervain D.J., Poirier R., Wollmer M.A., et al. Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Hum Mol Genet 13 1 (2004) 47-52
152. Perry III H.M., Horowitz M., Morley J.E., et al. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metabolism 48 (1999) 1028-1032
153. Gloth F.M., Gundberg C.M., Hollis B.W., et al. Vitamin D deficiency in homebound elderly persons. JAMA 274 (1995) 1683-1686
154. Morley J.E. Should all long-term care residents receive vitamin D?. J Am Med Dir Assoc 8 (2007) 69-70
155. Drinka P.J., Krause P.F., Nest L.J., et al. Determinants of vitamin D levels in nursing home residents. J Am Med Dir Assoc 8 (2007) 76-79
156. van der Wielen R.P., Lowik M.R., van den Berg H., et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 346 (1995) 207-210
157. Kalueff A.V., and Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care 10 (2007) 12-19
158. Buell J.S., and Dawson-Hugues B. Vitamin D and neurocognitive dysfunction: preventing "D"ecline?. Mol Aspects Med 29 (2008) 415-422
159. McCann J.C., and Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J 22 (2008) 982-1001
160. Garcion E., Wion-Barbot N., Montero-Menei C.N., et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 13 (2002) 100-105
161. Bourre J.M. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 10 (2006) 377-385
162. Brewer L.D., Thibault V., Chen K.C., et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 21 (2001) 98-108
163. McGrath J., Scragg R., Chant D., et al. No association between serum 25-hydroxyvitamin D3 level and performance on psychometric tests in NHANES III. Neuroepidemiology 29 (2007) 49-54
164. Jorde R., Waterloo K., Saleh F., et al. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels: the Tromsø study. J Neurol 253 (2006) 464-470
165. Wilkins C.H., Sheline Y.I., Roe C.M., et al. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 14 (2006) 1032-1340
166. Przybelski R.J., and Binkley N.C. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys 460 (2007) 202-205
167. Oudshoorn C., Mattace-Raso F.U., Van Der Velde N., et al. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 25 (2008) 539-543
168. Landfield P.W., and Cadwallader-Neal L. Long-term treatment with Calcitriol (1,25 (OH) 2 vit D3) retards a biomarker of hippocampal aging in rates. Neurobiol Aging 19 (1998) 469-477
169. Przybelski R., Agrawal S., Krueger D., et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int 19 (2008) 1621-1628
170. Tilvis R.S., Kähönen-Väre M.H., Jolkkonen J., et al. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol 59 (2004) 268-274
171. Schram M.T., Trompet S., Kamper A.M., et al. Serum calcium and cognitive function in old age. J Am Geriatr Soc 55 (2007) 1786-1792
172. Khachaturian Z.S. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci 747 (1994) 1-11
173. Smogorzewski M.J. Central nervous dysfunction in uremia. Am J Kidney Dis 38 Suppl 1 (2001) S122-S128
174. Ohrvall U., Akerstrom G., Ljunghall S., et al. Surgery for sporadic primary hyperparathyroidism in the elderly. World J Surg 18 (1994) 612-618
175. Farrer L.A., Cupples L.A., Myers R.H., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997) 1349-1356
176. Corder E., Ghebremedhin E., Taylor M., et al. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex and APOE polymorphism. Ann N Y Acad Sci 1019 (2004) 24-28
177. Burkhardt M., Foster J., Clarnette R., et al. Estrogen replacement therapy may improve memory functioning in the absence of APOE ε4. J Alzheimers Dis 6 (2004) 221-228
178. Bowen R., Smith M., Harris P., et al. Elevated luteinizing hormone expression co-localizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70 (2002) 514-518
179. Bowen R., Verdile G., Liu T., et al. Luteinizing hormone, a reproductive regulator that modulates the processing of the amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279 (2004) 20539-20545
180. Rodrigues M.A., Verdile G., Foster J.K., et al. Gonadotropins and cognition in older women. J Alzheimers Dis 13 (2008) 267-274
181. Meethal S.V., Smith M.A., Bowen R.L., et al. The gonadotropin connection in Alzheimer's disease. Endocrine 26 (2005) 317-326
182. Webber K.M., et al. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 5 (2007) 177-183
183. Short R., Bowen R., O'Brien P., et al. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76 (2001) 906-909
184. Manly J., Merchant C., Jacobs D., et al. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54 (2000) 833-837
185. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. C J Pineal Res 44 4 (2008) 341-347
186. Bob P., and Fedor-Freybergh P. Melatonin, consciousness and traumatic stress. Melatonin, consciousness, and traumatic stress. J Pineal Res 44 (2008) 341-347